Education
About Us
Working with TipRanks
Follow Us
Cartesian Therapeutics (RNAC)
NASDAQ:RNAC
RNAC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.85 - $41.87
Previous CloseN/A
Volume45.37K
Average Volume (3M)109.42K
Market Cap
$266.29M
Enterprise ValueN/A
Total Cash (Recent Filing)$212.61M
Total Debt (Recent Filing)$13.98M
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Aug 07, 2025EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding25,954,290
10 Day Avg. Volume87,224
30 Day Avg. Volume109,425
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)-331.56
Price to Sales (P/S)0.00
P/FCF Ratio-11.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$37.17Price Target Upside262.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Cartesian Therapeutics News
PremiumCompany Announcements
Cartesian Therapeutics Reports Q1 2025 Financial Results
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe company remains on track to initiate the Phase 3 AURORA trial of lead program Descartes-08 in generalized myasthenia gravis.
Financial StabilityCartesian ended 1Q25 with $182.1M in cash and equivalents which the company is guiding as sufficient to fund operations through completion of the Phase 3 AURORA trial and into mid-2027.
Safety And EfficacyThe safety profile seen in the 12mo update continued to support tolerability with no related AEs reported from 4mo through 12mo and no cases of CRS/ICANS or increased risk of hypogam.
Bears Say
Clinical ExecutionThere is anticipation for Phase 3 AURORA initiation and clinical execution and data updates across the broader AID pipeline.
Investor PerceptionThere remains significant upside potential in RNAC shares as Descartes-08/15's enabling features vs. DNA CAR T therapies in I&I continue to become better understood by investors.
Market CompetitionThe differentiated mRNA CAR-T approach and encouraging Phase 2b data for Descartes-08 have placed the company in a competitive position within the MG landscape.
---
RNAC FAQ
What was Cartesian Therapeutics’s price range in the past 12 months?
Cartesian Therapeutics lowest stock price was $8.85 and its highest was $41.87 in the past 12 months.
What is Cartesian Therapeutics’s market cap?
Cartesian Therapeutics’s market cap is $266.29M.
When is Cartesian Therapeutics’s upcoming earnings report date?
Cartesian Therapeutics’s upcoming earnings report date is Aug 07, 2025 which is in 80 days.
How were Cartesian Therapeutics’s earnings last quarter?
Cartesian Therapeutics released its earnings results on May 08, 2025. The company reported -$0.68 earnings per share for the quarter, beating the consensus estimate of -$0.701 by $0.021.
Is Cartesian Therapeutics overvalued?
According to Wall Street analysts Cartesian Therapeutics’s price is currently Undervalued.
Does Cartesian Therapeutics pay dividends?
Cartesian Therapeutics does not currently pay dividends.
What is Cartesian Therapeutics’s EPS estimate?
Cartesian Therapeutics’s EPS estimate is -0.82.
How many shares outstanding does Cartesian Therapeutics have?
Cartesian Therapeutics has 25,954,290 shares outstanding.
What happened to Cartesian Therapeutics’s price movement after its last earnings report?
Cartesian Therapeutics reported an EPS of -$0.68 in its last earnings report, beating expectations of -$0.701. Following the earnings report the stock price went up 2.66%.
Which hedge fund is a major shareholder of Cartesian Therapeutics?
Currently, no hedge funds are holding shares in RNAC
---
Cartesian Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.17 (262.28% Upside)
$37.17 (262.28% Upside)
Blogger Sentiment
Bullish
RNAC Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 100.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 0.1%
Last 30 Days ▲ 0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.04%
12-Months-Change
Fundamentals
Return on Equity
-938.38%
Trailing 12-Months
Asset Growth
25.81%
Trailing 12-Months
Company Description
Cartesian Therapeutics
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
---
RNAC Stock 12 Month Forecast
Average Price Target
$37.17
▲(262.28% Upside)
Technical Analysis
Oruka Therapeutics
―
Arcturus Therapeutics
―
aTyr Pharma
―
Verve Therapeutics
―
Aura Biosciences Inc
―
---